Peter Clausen - Jun 6, 2022 Form 4 Insider Report for Nuo Therapeutics, Inc. (AURX)

Role
CSO/COO
Signature
/s/ David E. Jorden, attorney-in-fact
Stock symbol
AURX
Transactions as of
Jun 6, 2022
Transactions value $
$0
Form type
4
Date filed
6/15/2022, 06:18 PM
Previous filing
May 2, 2022
Next filing
Aug 3, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AURX Option to Purchase Common Stock Award $0 +275K $0.00 275K Jun 6, 2022 Common Stock 275K $0.75 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The grant of these options was approved by the issuer's Board of Directors on March 4, 2022, subject to stockholder approval of an amendment to increase the number of shares available for issuance under the issuer's 2016 Omnibus Incentive Compensation Plan pursuant to which the options were granted. Stockholder approval was obtained by means of a written consent and the issuer filed a related Information Statement on Schedule 14C with the SEC on April 27, 2022. The stockholder approval became effective on June 6, 2022.
F2 One-third exercisable immediately on 03/04/2022 and the remainder exercisable quarterly over three years.